© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
February 2018
Future Shock: Embracing Disruption in the Immunotherapy Revolution
February 25, 2018
Article
Evidence-Based Oncology
Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.
With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
February 22, 2018
Article
Evidence-Based Oncology
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD
February 21, 2018
Article
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry
February 21, 2018
Article
Evidence-Based Oncology
Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"
February 21, 2018
Article
Evidence-Based Oncology
Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
February 20, 2018
Article
Evidence-Based Oncology
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.